CounterACT Core Resources

Core Resources  

• Anti-Convulsant Screening Program (ASP)  
  • CounterACT - ASP Collaboration to Identify Countermeasures Against Potential Chemical Threats [Summary] 
    •  Focus: In vitro and in vivo screening for anticonvulsant and neuroprotectant compounds
• CounterACT Efficacy Research Facility (CERF)
  •  Focus: Pilot and advanced (GLP) studies on the efficacy of candidate compounds
• CounterACT Preclinical Development Facility (CPDF)
  •  Focus: Pilot and advanced safety, chemistry and pharmacokinetic/dynamic (PK/PD) preclinical studies
• NIH Molecular Libraries Program: Pathways to Discovery
  • Focus: Enhance chemical biology efforts through High Throughput Screening (HTS) to obtain small molecule probes effective at modulating a given biological process or disease state

Related Information

• FDA Animal Model Quantification Program within the Drug Development Tools (DDT) Qualification Program
  • Animal Model FAQs
  • Animal Model Templates
• HHS & DoD Definition of Technology Readiness Levels (TRL) of Medical Countermeasures for Chemical Threats
  • When using these criteria, a medical countermeasure product should be rated at a particular level only after the sponsor has completed all activities listed in that level (e.g., a product is rated at TRL 4 once it completes all of the activities listed in TRL 4

Recent Developments in Medical Countermeasure (MCM) for Chemical Threats Research 

• Autoinjectors Offer Way to Treat Prolonged Seizures
• FDA Approves Pediatric Use of Chemical Poisoning Treatment - Protopam Chloride (pralidoxime chloride)